Instil Bio

TIL

市值 US$4008萬

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.

DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and provided a corporate update. Recent Highlights: Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates.

DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update. Recent Highlights Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates Cash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 2027 “We continue to make progress refining Instil's strategy and positioning the company for its next phase of growth,” said Bronson Crouch, Chief Executive Officer, Instil Bio.

Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond 2027 DALLAS, March 27, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its fourth quarter and full year 2025 financial results and provided a corporate update. Recent Highlights: In January 2026, Axion Bio, Inc., a wholly owned subsidiary of Instil, discontinued clinical development of AXN-2510 and entered into a termination agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. to terminate the license and collaboration agreement for AXN-2510 and AXN-27M.

NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

New York, New York--(Newsfile Corp. - January 20, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Instil Bio, Inc. ("Instil Bio, Inc.") (NASDAQ: TIL) concerning potential violations of the federal securities laws. Instil issued a press release on January 6, 2026, announcing that Axion Bio, Inc. ("Axion"), an Instil subsidiary, "has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc..